Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 121


Immunogenicity of a recombinant Rift Valley fever MP-12-NSm deletion vaccine candidate in calves.

Morrill JC, Laughlin RC, Lokugamage N, Wu J, Pugh R, Kanani P, Adams LG, Makino S, Peters CJ.

Vaccine. 2013 Oct 9;31(43):4988-94. doi: 10.1016/j.vaccine.2013.08.003. Epub 2013 Aug 27.


Safety and immunogenicity of recombinant Rift Valley fever MP-12 vaccine candidates in sheep.

Morrill JC, Laughlin RC, Lokugamage N, Pugh R, Sbrana E, Weise WJ, Adams LG, Makino S, Peters CJ.

Vaccine. 2013 Jan 7;31(3):559-65. doi: 10.1016/j.vaccine.2012.10.118. Epub 2012 Nov 12.


Safety of a mutagen-attenuated Rift Valley fever virus vaccine in fetal and neonatal bovids.

Morrill JC, Mebus CA, Peters CJ.

Am J Vet Res. 1997 Oct;58(10):1110-4.


Safety and immunogenicity of a mutagenized, live attenuated Rift Valley fever vaccine, MP-12, in a Phase 1 dose escalation and route comparison study in humans.

Pittman PR, McClain D, Quinn X, Coonan KM, Mangiafico J, Makuch RS, Morrill J, Peters CJ.

Vaccine. 2016 Jan 20;34(4):424-9. doi: 10.1016/j.vaccine.2015.12.030. Epub 2015 Dec 22.


Safety and efficacy of a mutagen-attenuated Rift Valley fever virus vaccine in cattle.

Morrill JC, Mebus CA, Peters CJ.

Am J Vet Res. 1997 Oct;58(10):1104-9.


Rift Valley fever virus vaccine lacking the NSs and NSm genes is safe, nonteratogenic, and confers protection from viremia, pyrexia, and abortion following challenge in adult and pregnant sheep.

Bird BH, Maartens LH, Campbell S, Erasmus BJ, Erickson BR, Dodd KA, Spiropoulou CF, Cannon D, Drew CP, Knust B, McElroy AK, Khristova ML, Albariño CG, Nichol ST.

J Virol. 2011 Dec;85(24):12901-9. doi: 10.1128/JVI.06046-11. Epub 2011 Oct 5.


Efficacy of a recombinant Rift Valley fever virus MP-12 with NSm deletion as a vaccine candidate in sheep.

Weingartl HM, Nfon CK, Zhang S, Marszal P, Wilson WC, Morrill JC, Bettinger GE, Peters CJ.

Vaccine. 2014 Apr 25;32(20):2345-9. doi: 10.1016/j.vaccine.2013.12.064. Epub 2014 Jan 24.


Rift Valley fever MP-12 vaccine Phase 2 clinical trial: Safety, immunogenicity, and genetic characterization of virus isolates.

Pittman PR, Norris SL, Brown ES, Ranadive MV, Schibly BA, Bettinger GE, Lokugamage N, Korman L, Morrill JC, Peters CJ.

Vaccine. 2016 Jan 20;34(4):523-30. doi: 10.1016/j.vaccine.2015.11.078. Epub 2015 Dec 17.


Protection of MP-12-vaccinated rhesus macaques against parenteral and aerosol challenge with virulent rift valley fever virus.

Morrill JC, Peters CJ.

J Infect Dis. 2011 Jul 15;204(2):229-36. doi: 10.1093/infdis/jir249.


Safety and efficacy of Rift Valley fever Smithburn and Clone 13 vaccines in calves.

von Teichman B, Engelbrecht A, Zulu G, Dungu B, Pardini A, Bouloy M.

Vaccine. 2011 Aug 5;29(34):5771-7. doi: 10.1016/j.vaccine.2011.05.055. Epub 2011 Jun 12.


Further evaluation of a mutagen-attenuated Rift Valley fever vaccine in sheep.

Morrill JC, Carpenter L, Taylor D, Ramsburg HH, Quance J, Peters CJ.

Vaccine. 1991 Jan;9(1):35-41.


Development of a novel, single-cycle replicable rift valley Fever vaccine.

Murakami S, Terasaki K, Ramirez SI, Morrill JC, Makino S.

PLoS Negl Trop Dis. 2014 Mar 20;8(3):e2746. doi: 10.1371/journal.pntd.0002746. eCollection 2014 Mar.


Immunogenicity and efficacy of a chimpanzee adenovirus-vectored Rift Valley fever vaccine in mice.

Warimwe GM, Lorenzo G, Lopez-Gil E, Reyes-Sandoval A, Cottingham MG, Spencer AJ, Collins KA, Dicks MD, Milicic A, Lall A, Furze J, Turner AV, Hill AV, Brun A, Gilbert SC.

Virol J. 2013 Dec 5;10:349. doi: 10.1186/1743-422X-10-349.


Evaluation of lamb and calf responses to Rift Valley fever MP-12 vaccination.

Wilson WC, Bawa B, Drolet BS, Lehiy C, Faburay B, Jasperson DC, Reister L, Gaudreault NN, Carlson J, Ma W, Morozov I, McVey DS, Richt JA.

Vet Microbiol. 2014 Aug 6;172(1-2):44-50. doi: 10.1016/j.vetmic.2014.04.007. Epub 2014 Apr 18.


Correlative Gene Expression to Protective Seroconversion in Rift Valley Fever Vaccinates.

Laughlin RC, Drake KL, Morrill JC, Adams LG.

PLoS One. 2016 Jan 19;11(1):e0147027. doi: 10.1371/journal.pone.0147027. eCollection 2016. Erratum in: PLoS One. 2016;11(5):e0156469.


[Study on DNA immune of envelope protein gene of Rift Valley Fever Virus].

Wang QH, Wang XJ, Hu S, Ge JY, Bu ZG.

Wei Sheng Wu Xue Bao. 2007 Aug;47(4):677-81. Chinese.


A glycoprotein subunit vaccine elicits a strong Rift Valley fever virus neutralizing antibody response in sheep.

Faburay B, Lebedev M, McVey DS, Wilson W, Morozov I, Young A, Richt JA.

Vector Borne Zoonotic Dis. 2014 Oct;14(10):746-56. doi: 10.1089/vbz.2014.1650.


Intramuscular inoculation of calves with an experimental Newcastle disease virus-based vector vaccine elicits neutralizing antibodies against Rift Valley fever virus.

Kortekaas J, Dekker A, de Boer SM, Weerdmeester K, Vloet RP, de Wit AA, Peeters BP, Moormann RJ.

Vaccine. 2010 Mar 8;28(11):2271-6. doi: 10.1016/j.vaccine.2010.01.001. Epub 2010 Jan 14.


A single immunization with MVA expressing GnGc glycoproteins promotes epitope-specific CD8+-T cell activation and protects immune-competent mice against a lethal RVFV infection.

López-Gil E, Lorenzo G, Hevia E, Borrego B, Eiden M, Groschup M, Gilbert SC, Brun A.

PLoS Negl Trop Dis. 2013 Jul 11;7(7):e2309. doi: 10.1371/journal.pntd.0002309. Print 2013.


Evaluation of the Efficacy, Potential for Vector Transmission, and Duration of Immunity of MP-12, an Attenuated Rift Valley Fever Virus Vaccine Candidate, in Sheep.

Miller MM, Bennett KE, Drolet BS, Lindsay R, Mecham JO, Reeves WK, Weingartl HM, Wilson WC.

Clin Vaccine Immunol. 2015 Aug;22(8):930-7. doi: 10.1128/CVI.00114-15. Epub 2015 Jun 3.

Supplemental Content

Support Center